title: [A long-term disease-free survival case of advanced rectal cancer with massive metastasis to the lateral pelvic and para-aortic lymph nodes].
abstract: A 42-year-old man with advanced rectal cancer underwent a low anterior resection with TME and pelvic lateral lymph-node and paraaortic lymph-node dissections. Pathological examination revealed as Type 2, 84 × 70 mm, tub 2 > por, A-SE, int, INF b, ly3, v1, pN3 (35/68), M1 (No. 216: 24/37), Stage IV (Cur B) by Japanese Classification of Colorectal Carcinoma. Three kinds of chemotherapy, 3 courses of irinotecan and bolus fluorouracil plus Leucovorin (IFL), 4 courses of irinotecan and S-1 (IRIS), and one-year of S-1 were administered sequentially. After 5 years from the operation, the patient survived and showed no sign of recurrence. Aggressive lymph-node dissection for rectal cancer patients with massive lymph-node metastasis followed by intensive chemotherapy may result in long-term survival.
authors.affiliation: Dept. of Gastrointestinal Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases.
authors.forename: Tatsushi
authors.initials: T
authors.lastname: Shingai
authors.forename: Masayuki
authors.initials: M
authors.lastname: Ohue
authors.forename: Shingo
authors.initials: S
authors.lastname: Noura
authors.forename: Shingo
authors.initials: S
authors.lastname: Kano
authors.forename: Kunihito
authors.initials: K
authors.lastname: Gotoh
authors.forename: Masaaki
authors.initials: M
authors.lastname: Motoori
authors.forename: Hidenori
authors.initials: H
authors.lastname: Takahashi
authors.forename: Kentaro
authors.initials: K
authors.lastname: Kishi
authors.forename: Terumasa
authors.initials: T
authors.lastname: Yamada
authors.forename: Isao
authors.initials: I
authors.lastname: Miyashiro
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ohigashi
authors.forename: Masahiko
authors.initials: M
authors.lastname: Yano
authors.forename: Osamu
authors.initials: O
authors.lastname: Ishikawa
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001012:Aorta, Abdominal; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis / Q000473:pathology*; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage; D010388:Pelvis; D012004:Rectal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D005641:Tegafur / Q000008:administration & dosage; D014803:Vitamin B Complex / Q000008:administration & dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; D014803:Vitamin B Complex; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin